SCINTIX® therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
SELF-DRIVING RADIOTHERAPY
Cancer is talking. We’re listening.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our machine uses to manage motion and treat solid tumors of any stage disease.
Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
New codes and payment expected to facilitate clinical adoption of novel cancer treatment option HAYWARD, Calif., Jan. 11, 2024 – RefleXion Medical, Inc., a therapeutic oncology company, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a national payment rate for RefleXion’s SCINTIX® biology-guided radiotherapy using CMS’ New Technology (NT) Ambulatory […]
For patients battling cancer, little is more important than knowing exactly where they stand in the course of the disease. When a malignant tumor spreads from its original location to additional sites in the body, this means the disease has “metastasized.” If the disease has spread to many locations, this is sometimes termed polymetastatic disease. […]